Moderna and Merck & Co. have developed a cancer vaccine that cuts the risk of death or recurrence of most deadly skin cancer by 44 percent compared to Merck's Keytruda on its own, according to researchers.
A study by the Netherlands Institute of Neuroscience found that the human brain appears to understand what it sees differently depending on what it expects.